178 related articles for article (PubMed ID: 21749214)
1. Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility.
Kopits IM; Chen C; Roberts JS; Uhlmann W; Green RC
Genet Test Mol Biomarkers; 2011 Dec; 15(12):871-5. PubMed ID: 21749214
[TBL] [Abstract][Full Text] [Related]
2. Cost sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing.
Matro JM; Ruth KJ; Wong YN; McCully KC; Rybak CM; Meropol NJ; Hall MJ
J Genet Couns; 2014 Dec; 23(6):1002-11. PubMed ID: 24794065
[TBL] [Abstract][Full Text] [Related]
3. Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.
Cassidy MR; Roberts JS; Bird TD; Steinbart EJ; Cupples LA; Chen CA; Linnenbringer E; Green RC
Alzheimers Dement; 2008 Nov; 4(6):406-13. PubMed ID: 19012865
[TBL] [Abstract][Full Text] [Related]
4. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.
Chao S; Roberts JS; Marteau TM; Silliman R; Cupples LA; Green RC
Alzheimer Dis Assoc Disord; 2008; 22(1):94-7. PubMed ID: 18317253
[TBL] [Abstract][Full Text] [Related]
5. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.
Zick CD; Mathews CJ; Roberts JS; Cook-Deegan R; Pokorski RJ; Green RC
Health Aff (Millwood); 2005; 24(2):483-90. PubMed ID: 15757934
[TBL] [Abstract][Full Text] [Related]
6. Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease.
Ashida S; Koehly LM; Roberts JS; Chen CA; Hiraki S; Green RC
J Health Commun; 2009 Dec; 14(8):768-84. PubMed ID: 20029710
[TBL] [Abstract][Full Text] [Related]
7. Disclosure of APOE genotype for risk of Alzheimer's disease.
Green RC; Roberts JS; Cupples LA; Relkin NR; Whitehouse PJ; Brown T; Eckert SL; Butson M; Sadovnick AD; Quaid KA; Chen C; Cook-Deegan R; Farrer LA;
N Engl J Med; 2009 Jul; 361(3):245-54. PubMed ID: 19605829
[TBL] [Abstract][Full Text] [Related]
8. Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics.
Roberts JS; Christensen KD; Green RC
Clin Genet; 2011 Nov; 80(5):407-14. PubMed ID: 21696382
[TBL] [Abstract][Full Text] [Related]
9. Predictive genetic testing for Alzheimer's disease: impact upon risk perception.
Marteau TM; Roberts S; LaRusse S; Green RC
Risk Anal; 2005 Apr; 25(2):397-404. PubMed ID: 15876213
[TBL] [Abstract][Full Text] [Related]
10. Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial.
Roberts JS; Barber M; Brown TM; Cupples LA; Farrer LA; LaRusse SA; Post SG; Quaid KA; Ravdin LD; Relkin NR; Sadovnick AD; Whitehouse PJ; Woodard JL; Green RC
Genet Med; 2004; 6(4):197-203. PubMed ID: 15266207
[TBL] [Abstract][Full Text] [Related]
11. Medicolegal, employment, and insurance issues in APOE genotyping and Alzheimer's disease.
Kapp MB
Ann N Y Acad Sci; 1996 Dec; 802():139-48. PubMed ID: 8993493
[No Abstract] [Full Text] [Related]
12. Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates.
Fanshawe TR; Prevost AT; Roberts JS; Green RC; Armstrong D; Marteau TM
Genet Test; 2008 Sep; 12(3):381-6. PubMed ID: 18666860
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease.
Martinez M; Campion D; Brice A; Hannequin D; Dubois B; Didierjean O; Michon A; Thomas-Anterion C; Puel M; Frebourg T; Agid Y; Clerget-Darpoux F
Arch Neurol; 1998 Jun; 55(6):810-6. PubMed ID: 9626772
[TBL] [Abstract][Full Text] [Related]
14. Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease.
LaRusse S; Roberts JS; Marteau TM; Katzen H; Linnenbringer EL; Barber M; Whitehouse P; Quaid K; Brown T; Green RC; Relkin NR
Genet Med; 2005 Jan; 7(1):48-53. PubMed ID: 15654228
[TBL] [Abstract][Full Text] [Related]
15. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.
Klages JD; Fisk JD; Rockwood K
Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature.
Marshe VS; Gorbovskaya I; Kanji S; Kish M; Müller DJ
J Neural Transm (Vienna); 2019 Jan; 126(1):65-85. PubMed ID: 30382407
[TBL] [Abstract][Full Text] [Related]
17. "Choosing Wisely": Apolipoprotein E Genetic Testing for the Diagnosis of Alzheimer's Disease in Dementia Clinics.
Yang HJ; Kang NR; Jung YE; Kim MD; Jeong HG; Lee TJ; Han JW; Kim KW; Park JH
J Alzheimers Dis; 2020; 74(4):1253-1260. PubMed ID: 32176640
[TBL] [Abstract][Full Text] [Related]
18. Psychosocial factors associated with the public's willingness to pay for genetic testing for cancer risk: a structural equations model.
Bosompra K; Ashikaga T; Flynn BS; Worden JK; Solomon LJ
Health Educ Res; 2001 Apr; 16(2):157-72. PubMed ID: 11357857
[TBL] [Abstract][Full Text] [Related]
19. Patients' willingness-to-pay for an Alzheimer's disease medication in Canada.
Oremus M; Tarride JE; Pullenayegum E; Clayton N; ; Raina P
Patient; 2013; 6(3):161-8. PubMed ID: 23716166
[TBL] [Abstract][Full Text] [Related]
20. Public attitudes about genetic testing for Alzheimer's disease.
Neumann PJ; Hammitt JK; Mueller C; Fillit HM; Hill J; Tetteh NA; Kosik KS
Health Aff (Millwood); 2001; 20(5):252-64. PubMed ID: 11558711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
